OctoPlus signs drug development contract with The Medicines Company

13-Jul-2010 - Netherlands

OctoPlus N.V. announced that it has signed a pharmaceutical development and manufacturing contract with a new client, US-based The Medicines Company. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.

Under the contract terms, OctoPlus will perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances